RegenxBio raises $70.5M series D

Gene therapy company RegenxBio Inc. (Rockville, Md.) raised $70.5 million in an oversubscribed series D round led by new investor Vivo Capital and existing investors Venrock and Brookside Capital. Other investors included Janus Capital, Jennison Associates, Perceptive Advisors, QVT Financial, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management, Foresite Capital, RTW Investments, two undisclosed investment funds, Deerfield Management and Fidelity Biosciences.

RegenxBio has three programs in preclinical development, including RGX-111 to treat mucopolysaccharidosis I (MPS-I; Hurler syndrome). The company expects to begin a clinical study early next year of the adeno-associated viral (AAV) gene therapy that delivers a normal copy of the alpha-L-iduronidase ( IDUA) gene to the CNS. ...